Chemoinformaics analysis of 2,3,4,5-Tetramethylhexa-1,4-diene
| Molecular Weight | 138.254 | nRot | 2 |
| Heavy Atom Molecular Weight | 120.11 | nRig | 2 |
| Exact Molecular Weight | 138.141 | nRing | 0 |
| Solubility: LogS | -3.963 | nHRing | 0 |
| Solubility: LogP | 4.2 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 28 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 10 | No. of Aromatic Carbocycles | 0 |
| nHetero | 0 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 18 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 10 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 0 | No. of Arom Bond | 0 |
| nHA | 0 | APOL | 28.7023 |
| nHD | 0 | BPOL | 18.0577 |
| QED | 0.512 |
| Synth | 3.706 |
| Natural Product Likeliness | 1.007 |
| NR-PPAR-gamma | 0.005 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Rejected |
| Pgp-inh | 0.829 |
| Pgp-sub | 0.251 |
| HIA | 0.007 |
| CACO-2 | -4.543 |
| MDCK | 0.0000157 |
| BBB | 0.988 |
| PPB | 0.946598 |
| VDSS | 4.503 |
| FU | 0.0424449 |
| CYP1A2-inh | 0.659 |
| CYP1A2-sub | 0.772 |
| CYP2c19-inh | 0.125 |
| CYP2c19-sub | 0.928 |
| CYP2c9-inh | 0.08 |
| CYP2c9-sub | 0.392 |
| CYP2d6-inh | 0.037 |
| CYP2d6-sub | 0.372 |
| CYP3a4-inh | 0.045 |
| CYP3a4-sub | 0.371 |
| CL | 13.239 |
| T12 | 0.209 |
| hERG | 0.014 |
| Ames | 0.007 |
| ROA | 0.013 |
| SkinSen | 0.05 |
| Carcinogencity | 0.098 |
| EI | 0.971 |
| Respiratory | 0.152 |
| NR-Aromatase | 0.003 |
| Antiviral | No |
| Prediction | 0.936926 |